TOKYO--(BUSINESS WIRE)--Sept. 15, 2006--GNI Ltd, a leading biopharmaceutical company in Asia, and its Chinese affiliate Shanghai Genomics, announced today that their researchers had identified an important regulator and its associated signaling cascade in X-linked lymphoproliferative disease (XLP), a human immunological disorder. The findings of the research are to be published by the Proceedings of the National Academy of Sciences of the United States of America (PNAS), one of the world’s most-cited multidisciplinary scientific serials, during the week of September 11, 2006.
